343 related articles for article (PubMed ID: 24843148)
1. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.
Ankomah P; Levin BR
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8331-8. PubMed ID: 24843148
[TBL] [Abstract][Full Text] [Related]
2. Exploring the role of the immune response in preventing antibiotic resistance.
Handel A; Margolis E; Levin BR
J Theor Biol; 2009 Feb; 256(4):655-62. PubMed ID: 19056402
[TBL] [Abstract][Full Text] [Related]
3. The population dynamics of antimicrobial chemotherapy.
Lipsitch M; Levin BR
Antimicrob Agents Chemother; 1997 Feb; 41(2):363-73. PubMed ID: 9021193
[TBL] [Abstract][Full Text] [Related]
4. Phagocytes, Antibiotics, and Self-Limiting Bacterial Infections.
Levin BR; Baquero F; Ankomah PP; McCall IC
Trends Microbiol; 2017 Nov; 25(11):878-892. PubMed ID: 28843668
[TBL] [Abstract][Full Text] [Related]
5. Multi-step vs. single-step resistance evolution under different drugs, pharmacokinetics, and treatment regimens.
Igler C; Rolff J; Regoes R
Elife; 2021 May; 10():. PubMed ID: 34001313
[TBL] [Abstract][Full Text] [Related]
6. Bacterial fitness shapes the population dynamics of antibiotic-resistant and -susceptible bacteria in a model of combined antibiotic and anti-virulence treatment.
Ternent L; Dyson RJ; Krachler AM; Jabbari S
J Theor Biol; 2015 May; 372():1-11. PubMed ID: 25701634
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic control of antibiotic resistance in hospitals: a simulation study.
Haber M; Levin BR; Kramarz P
BMC Infect Dis; 2010 Aug; 10():254. PubMed ID: 20738872
[TBL] [Abstract][Full Text] [Related]
8. What do we really know about antibiotic pharmacodynamics?
Gunderson BW; Ross GH; Ibrahim KH; Rotschafer JC
Pharmacotherapy; 2001 Nov; 21(11 Pt 2):302S-318S. PubMed ID: 11714222
[TBL] [Abstract][Full Text] [Related]
9. The pharmaco -, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations.
Ankomah P; Johnson PJ; Levin BR
PLoS Pathog; 2013; 9(4):e1003300. PubMed ID: 23593006
[TBL] [Abstract][Full Text] [Related]
10. Treatment timing shifts the benefits of short and long antibiotic treatment over infection.
Gjini E; Paupério FFS; Ganusov VV
Evol Med Public Health; 2020; 2020(1):249-263. PubMed ID: 33376597
[TBL] [Abstract][Full Text] [Related]
11. Evolutionary optimisation of antibiotic dosing regimens for bacteria with different levels of resistance.
Goranova M; Ochoa G; Maier P; Hoyle A
Artif Intell Med; 2022 Nov; 133():102405. PubMed ID: 36328666
[TBL] [Abstract][Full Text] [Related]
12. Evaluating treatment protocols to prevent antibiotic resistance.
Bonhoeffer S; Lipsitch M; Levin BR
Proc Natl Acad Sci U S A; 1997 Oct; 94(22):12106-11. PubMed ID: 9342370
[TBL] [Abstract][Full Text] [Related]
13. Beyond dose: Pulsed antibiotic treatment schedules can maintain individual benefit while reducing resistance.
Baker CM; Ferrari MJ; Shea K
Sci Rep; 2018 Apr; 8(1):5866. PubMed ID: 29650999
[TBL] [Abstract][Full Text] [Related]
14. Optimising Antibiotic Usage to Treat Bacterial Infections.
Paterson IK; Hoyle A; Ochoa G; Baker-Austin C; Taylor NG
Sci Rep; 2016 Nov; 6():37853. PubMed ID: 27892497
[TBL] [Abstract][Full Text] [Related]
15. Mathematical model predicts anti-adhesion-antibiotic-debridement combination therapies can clear an antibiotic resistant infection.
Roberts PA; Huebinger RM; Keen E; Krachler AM; Jabbari S
PLoS Comput Biol; 2019 Jul; 15(7):e1007211. PubMed ID: 31335907
[TBL] [Abstract][Full Text] [Related]
16. Treatment failures with broad-spectrum antibiotics.
Norrby SR
Scand J Infect Dis Suppl; 1991; 78():64-70. PubMed ID: 1947824
[TBL] [Abstract][Full Text] [Related]
17. The within-host population dynamics of antibacterial chemotherapy: conditions for the evolution of resistance.
Lipsitch M; Levin BR
Ciba Found Symp; 1997; 207():112-27; discussion 127-30. PubMed ID: 9189638
[TBL] [Abstract][Full Text] [Related]
18. How preclinical infection models help define antibiotic doses in the clinic.
Tängdén T; Lundberg CV; Friberg LE; Huttner A
Int J Antimicrob Agents; 2020 Aug; 56(2):106008. PubMed ID: 32389722
[TBL] [Abstract][Full Text] [Related]
19. "One-size-fits-all"? Optimizing treatment duration for bacterial infections.
Geli P; Laxminarayan R; Dunne M; Smith DL
PLoS One; 2012; 7(1):e29838. PubMed ID: 22253798
[TBL] [Abstract][Full Text] [Related]
20. An experimental analysis of the curative action of penicillin in acute bacterial infections. III. The effect of suppuration upon the antibacterial action of the drug.
SMITH MR; WOOD WB
J Exp Med; 1956 Apr; 103(4):509-22. PubMed ID: 13306859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
